You can download the GlucosePATH QuickStart Guide here.

PATH is a computer program designed to help healthcare providers and patients make decisions about the medical treatment of Type 2 Diabetes. PATH individualizes therapy to account for drug interactions, side effects, underlying medical benefits, ease of use, and drug costs. Recommendations are presented with a score from 0 (the worst) to 100 (the best) along with the most important information for patients to know about risks and benefits.

Use GlucosePATH to help with the complex task of choosing an optimal regimen for patients with Type 2 Diabetes. There are more than 60 FDA-approved treatments for type 2 diabetes, each with different doses, efficacy, side effects, and cost. That means there are millions of possible drug regimens to consider. GlucosePATH will evaluate all of them, using a standard set of rules, to identify the best ones for your patient.

GlucosePATH evaluates all possible combinations of medications for a given patient's data, using five criteria: A1c Reduction, Cost, Weight Change, Side Effects, and Likely Adherence. Recommendations are presented with a score from 0 (the worst) to 100 (the best) along with the most important information for patients to know about risks and benefits.

Understanding cost in healthcare is critically important when making decisions about care. PATH looks entirely at the cost to the patient in order to maintain a patient centered approach. Currently, PATH uses common core formulary and copay structures with the understanding that individual plans may vary. PATH also keeps an updated list of manufacturer coupons that can be applied for cost.

Currently, medicare costs use a formula which estimates the impact of the medication in terms of the coverage gap for most patients and generates an average monthly cost (accounting for the “donut hole”). Expensive medicines for other conditions may affect the cost in terms of total cost, though the ranking of the medications will remain largely intact.

Currently, PATH focuses on the treatment of hyperglycemia and the peripheral benefits and risk of anti-hyperglycemic agents. While important, choice of medicines for cholesterol and high blood pressure are not currently included and should be individually evaluated by the patient’s health care provider.

PATH is not currently available as a commercial product; it is available for pre-release evaluation.